Clinical Trial Site

Toronto M5B 1W8

2 studies enrolling now · 8 studies all time

What they study most

ANCA-Associated Vasculitis, Amyloid Neuropathies, Amyloid Neuropathies, Familial, Amyloidosis, Hereditary, Amyloidosis, Hereditary, Transthyretin-Related, Cerebral Amyloid Angiopathy, Early-Onset Alzheimer Disease, Familial Transthyretin Cardiac Amyloidosis, Hereditary Hemorrhagic Telangiectasia, High Cardiovascular Risk, Hypertension, RTT

Studies at this site

• A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy — Recruiting now
• A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD — Recruiting now
• A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) — Running, not enrolling
• Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) — Completed
• A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM — Stopped early
• A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis — Completed
• A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome — Stopped early
• ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) — Completed